Clinical Trials Logo

Daboia Siamensis Envenoming clinical trials

View clinical trials related to Daboia Siamensis Envenoming.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT04210141 Suspended - Clinical trials for Daboia Siamensis Envenoming

Optimal Dose of Antivenom for Daboia Siamensis Envenomings

ODADS
Start date: April 2025
Phase: Phase 2
Study type: Interventional

The aim of the study is to identify an 'optimal' initial dosing of the new Burma Pharmaceutical Industry (BPI) lyophilized mono-specific antivenom for patients with systemic Daboia siamensis envenoming. The initial dosing will aim to reverse venom-induced coagulopathy (as demonstrated by a negative 20 minutes Whole Blood Clotting Time (20WBCT) at 6 hours in 95% of patients whilst causing less than 5% anaphylactic reaction.